|
1
|
Cohen S: Purification of the receptor for
epidermal growth factor from A-431 cells: Its function as a tyrosyl
kinase. Methods Enzymol. 99:379–387. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mendelsohn J and Baselga J: Status of
epidermal growth factor receptor antagonists in the biology and
treatment of cancer. J Clin Oncol. 21:2787–2799. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Herbst RS, Maddox AM, Rothenberg ML, Small
EJ, Rubin EH, Baselga J, Rojo F, Hong WK, Swaisland H, Averbuch SD,
et al: Selective oral epidermal growth factor receptor tyrosine
kinase inhibitor ZD1839 is generally well-tolerated and has
activity in non-small-cell lung cancer and other solid tumors:
Results of a phase I trial. J Clin Oncol. 20:3815–3825. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Thatcher N, Chang A, Parikh P, Pereira
Rodrigues J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH,
Pemberton K, Archer V and Carroll K: Gefitinib plus best supportive
care in previously treated patients with refractory advanced
non-small-cell lung cancer: Results from a randomised,
placebo-controlled, multicentre study (Iressa Survival Evaluation
in Lung Cancer). Lancet. 366:1527–1537. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Han SW, Kim TY, Hwang PG, Jeong S, Kim J,
Choi IS, Oh DY, Kim JH, Kim DW, Chung DH, et al: Predictive and
prognostic impact of epidermal growth factor receptor mutation in
non-small-cell lung cancer patients treated with gefitinib. J Clin
Oncol. 23:2493–2501. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Huang SF, Liu HP, Li LH, Ku YC, Fu YN,
Tsai HY, Chen YT, Lin YF, Chang WC, Kuo HP, et al: High frequency
of epidermal growth factor receptor mutations with complex patterns
in non-small cell lung cancers related to gefitinib responsiveness
in Taiwan. Clin Cancer Res. 10:8195–8203. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pao W and Miller VA: Epidermal growth
factor receptor mutations, small-molecule kinase inhibitors, and
non-small-cell lung cancer: Current knowledge and future
directions. J Clin Oncol. 23:2556–2568. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kris MG, Johnson BE, Berry LD, Kwiatkowski
DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson
SL, Su PF, et al: Using multiplexed assays of oncogenic drivers in
lung cancers to select targeted drugs. JAMA. 311:1998–2006. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jackman DM, Miller VA, Cioffredi LA, Yeap
BY, Jänne PA, Riely GJ, Ruiz MG, Giaccone G, Sequist LV and Johnson
BE: Impact of epidermal growth factor receptor and KRAS mutations
on clinical outcomes in previously untreated non-small cell lung
cancer patients: Results of an online tumor registry of clinical
trials. Clin Cancer Res. 15:5267–5273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rosell R, Moran T, Queralt C, Porta R,
Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M,
et al: Screening for epidermal growth factor receptor mutations in
lung cancer. N Engl J Med. 361:958–967. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jukna A, Montanari G, Mengoli MC, Cavazza
A, Covi M, Barbieri F, Bertolini F and Rossi G: Squamous cell
carcinoma ‘Transformation’ concurrent with secondary T790M mutaton
in resistant EGFR-mutated adenocarcinomas. J Thorac Oncol.
11:e49–e51. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kuiper JL, Ronden MI, Becker A, Heideman
DA, van Hengel P, Ylstra B, Thunnissen E and Smit EF:
Transformation to a squamous cell carcinoma phenotype of an
EGFR-mutated NSCLC patient after treatment with an EGFR-tyrosine
kinse inhibitor. J Clin Pathol. 68:320–321. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Levin PA, Mayer M, Hoskin S, Sailors J,
Oliver DH and Gerber DE: Histologic transformation from
adenocarcinoma to squamous cell carcinoma as a mechanism of
resistance to EGFR inhibition. J Thorac Oncol. 10:e86–e88. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Billah S, Stewart J, Staerkel G, Chen S,
Gong Y and Guo M: EGFR and KRAS mutations in lung carcinoma:
Molecular testing by using cytology specimens. Cancer
Cytopathology. 119:111–117. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pao W, Kris MG, Iafrate AJ, Ladanyi M,
Jänne PA, Wistuba II, Miake-Lye R, Herbst RS, Carbone DP, Johnson
BE and Lynch TJ: Integration of molecular profiling into the lung
cancer clinic. Clin Cancer Res. 15:5317–5322. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Goldstraw P, Crowley J, Chansky K, Giroux
DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V and Sobin L:
International Association for the Study of Lung Cancer
International Staging Committee; Participating Institutions: The
IASLC lung cancer staging project: Proposals for the revision of
the TNM stage groupings in the forthcoming (seventh) edition of the
TNM classification of malignant tumours. J Thorac Oncol. 2:706–714.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu J, Zhao R and Zhang J and Zhang J:
ARMS for EGFR mutation analysis of cytologic and corresponding lung
adenocarcinoma histologic specimens. J Cancer Res Clin Oncol.
141:221–227. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yatabe Y, Matsuo K and Mitsudomi T:
Heterogeneous distribution of EGFR mutations is extremely rare in
lung adenocarcinoma. J Clin Oncol. 29:2972–2977. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Travis WD: Pathology of lung cancer. Clin
Chest Med. 32:669–692. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Travis WD, Brambilla E, Noguchi M,
Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ,
Van Schil PE, et al: International association for the study of
lung cancer/american thoracic society/european respiratory society
international multidisciplinary classification of lung
adenocarcinoma. J Thorac Oncol. 6:244–285. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lu J, Wang W, Xu M, Li Y, Chen C and Wang
X: A global view of regulatory networks in lung cancer: An approach
to understand homogeneity and heterogeneity. Semin Cancer Biol.
42:31–38. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: Gefitinib or chemotherapy for non-small-cell lung cancer
with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Petrelli F, Borgonovo K, Cabiddu M and
Barni S: Efficacy of EGFR tyrosine kinase inhibitors in patients
with EGFR-mutated non-small-cell lung cancer: A meta-analysis of 13
randomized trials. Clin Lung Cancer. 13:107–114. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rekhtman N, Paik PK, Arcila ME, Tafe LJ,
Oxnard GR, Moreira AL, Travis WD, Zakowski MF, Kris MG and Ladanyi
M: Clarifying the spectrum of driver oncogene mutations in
biomarker-verified squamous carcinoma of lung: Lack of EGFR/KRAS
and presence of PIK3CA/AKT1 mutations. Clin Cancer Res.
18:1167–1176. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang L, Ma S, Song X, Han B, Cheng Y,
Huang C, Yang S, Liu X, Liu Y, Lu S, et al: Gefitinib versus
placebo as maintenance therapy in patients with locally advanced or
metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): A
multicentre, double-blind randomised phase 3 trial. Lancet Oncol.
13:466–475. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Clark GM, Zborowski DM, Santabarbara P,
Ding K, Whitehead M, Seymour L and Shepherd FA: National Cancer
Institute of Canada Clinical Trials Group: Smoking history and
epidermal growth factor receptor expression as predictors of
survival benefit from erlotinib for patients with non-small-cell
lung cancer in the National Cancer Institute of Canada Clinical
Trials Group study BR.21. Clin Lung Cancer. 7:389–394. 2016.
View Article : Google Scholar
|
|
30
|
Cappuzzo F, Ciuleanu T, Stelmakh L,
Cicenas S, Szczésna A, Juhász E, Esteban E, Molinier O, Brugger W,
Melezínek I, et al: Erlotinib as maintenance treatment in advanced
non-small-cell lung cancer: A multicentre, randomised,
placebo-controlled phase 3 study. Lancet Oncol. 11:521–529. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Owonikoko TK, Ragin CC, Belani CP, Oton
AB, Gooding WE, Taioli E and Ramalingam SS: Lung cancer in elderly
patients: An analysis of the surveillance, epidemiology, and end
results database. J Clin Oncol. 25:5570–5577. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Thomas A, Chen Y, Yu T, Jakopovic M and
Giaccone G: Trends and characteristics of young non-small cell lung
cancer patients in the United States. Front Oncol. 5:1132015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Miyoshi S, Hamada H, Ito R, Hamaguchi N,
Kadowaki T and Higaki J: Successful treatment of non-small cell
lung cancer by gefitinib in an elderly patient with poor
performance status. Nihon Ronen Igakkai Zasshi. 45:338–342.
2008.(In Japanese). View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xu J, Zhang Y, Jin B, Chu T, Dong X, Yang
H, Wu D, Lou Y, Zhang X, Wang H and Han B: Efficacy of EGFR
tyrosine kinase inhibitors for non-adenocarcinoma lung cancer
patients harboring EGFR-sensitizing mutations in China. J Cancer
Res Clin Oncol. 142:1325–1330. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ameratunga M, Pavlakis N, Gebski V, Broad
A and Khasraw M: Epidermal growth factor receptor-tyrosine kinase
inhibitors in advanced squamous cell carcinoma of the lung: A
meta-analysis. Asia Pac J Clin Oncol. 10:273–278. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cobo M, Gutiérrez V, Rodelo L, López O,
Ruiz M and Godoy A: Afatinib in patients with squamous cell
carcinoma of the lung: Current context and the option of oral
treatment. Med Clin (Barc). 146 Suppl 1:S25–S29. 2016.(In Spanish).
View Article : Google Scholar
|
